근거중심한의약 DB
Home > 한의약융합데이터센터 > 근거중심한의약 DBTitle | Seven-Year Follow-up of Children Born to Women in a Randomized Trial of Prenatal DHA Supplementation. |
---|---|
Authors | Gould JF, Treyvaud K, Yelland LN, Anderson PJ, Smithers LG, McPhee AJ, Makrides M. |
Journal | JAMA. |
Year | 2017 |
Vol (Issue) | 317(11) |
Page | 1173-75. |
doi | 10.1001/jama.2016.21303. |
PMID | |
Url | |
MeSH | Age Factors |
Keywords | |
한글 키워드 | |
KMCRIC Summary & Commentary |
|
Korean Study | |
Abstract | The sale of prenatal supplements with docosahexaenoic acid (DHA) continues to increase, despite little evidence of benefit to offspring neurodevelopment.1 We randomized pregnant women to receive 800 mg of DHA daily or a placebo during the last half of pregnancy and found no group differences in cognitive, language, and motor development at 18 months of age, although secondary analyses revealed less cognitive delay but lower language scores in the DHA group.2 At 4 years of age there was no benefit of DHA supplementation in general intelligence, language, and executive functioning, and a possible negative effect on parent-rated behavior and executive functioning.3 This follow-up was designed to evaluate the effect of prenatal DHA on intelligence quotient (IQ) at 7 years, the earliest age at which adult performance can be indicated. |
국문초록 | |
Language | 영어 |
첨부파일 |